Neko Health, the preventive care and longevity-focused startup backed by Spotify founder Daniel Ek, has announced its expansion into the United States following a 700 million dollar funding round. The company will open its first American clinic in New York this year, with plans for rapid national rollout. Neko operates private facilities that utilize artificial intelligence and proprietary medical hardware to conduct comprehensive full-body imaging and laboratory blood tests. The service is engineered to detect early-stage markers for conditions such as skin cancer, cardiovascular disease, and diabetes, shifting medical attention from reactive treatment to proactive prevention. Currently operating eight clinics across London and Stockholm, Neko has generated significant consumer demand, with more than 350,000 individuals on its global waitlist and approximately 100,000 clients having completed assessments. While European pricing is set at roughly 299 British pounds and 2,750 Swedish kronor, the startup has not yet disclosed pricing for its US locations. The New York waitlist is now open, though specific dates for the clinic launch and subsequent American cities remain undefined. The latest capital infusion was secured from a consortium of technology executives, entertainment figures, and investment firms, including Meta co-founder Mark Zuckerberg and Priscilla Chan, musician Will.i.am, former professional tennis player Maria Sharapova, ex-footballer Thierry Henry, and Reddit cofounder Alexis Ohanian. According to reported estimates, the financing elevates Neko corporate valuation to approximately 7 billion dollars, up from its previous 260 million dollar raise in early 2025. Co-founder and Chief Executive Hjalmar Nilsonne stated that the funding will primarily accelerate the US market entry and finance continued technological development aimed at scaling preventive diagnostics globally. Neko expansion arrives amid a broader industry shift toward decentralized, consumer-driven healthcare and longevity optimization. Traditional medical systems have long struggled with capacity constraints and a reactive posture, leaving a market gap for accessible, technology-enabled early screening. By integrating automated imaging systems and data analytics into a streamlined clinic experience, Neko seeks to standardize and scale health monitoring for an increasingly health-conscious demographic. Industry analysts note that while the preventive diagnostics sector has attracted considerable investment, operational scalability and regulatory compliance will remain critical hurdles as the company transitions from a European pilot to a large-scale American healthcare provider.